Treatment Gap in Nephroprotection: Analysis of Prior Use of Drugs with Nephroprotective Effects in Patients with Incidental Diagnosis of Diabetic Kidney Disease

Simple item page
AudienciaPúblico en generales_ES
CoberturaMéxicoes_ES
Fecha de ingreso2026-09-15T00:31:40Z
Fecha de publicación2025-10-01
ResumenBackground: The diagnosis and staging of Chronic Kidney Disease (CKD) are based on an assesment that primarily includes estimated glomerular filtration rate (eGFR) and albuminuria range. However, CKD is often diagnosed incidentally in hospitalized patients. To assess the impact of the previous use of drugs with nephroprotective effects (DNE)- such as sodium-glucose co-transporter 2 inhibitors (iSGLT2), GLP-1 receptor agonists (GLP-1ra), renin-angiotensin system inhibitors (RASi), and/or nonsteroidal mineralocorticoid receptor antagonists (nsMRA)- on patients with an incidental CKD diagnosis during hospitalization in the Internal Medicin ward. Methods: Observational, cross-sectional study in patients admitted to the Internal Medicin ward over a six-month period. Patients with Diabetes Mellitus Type 2 (DM2) and an incidental diagnosis of CKD defined as an albumin-to-creatinine ratio (ACR) over 30 mg/g and eGFR below 60 mL/min/1.73 m2, were selected. Previous use of DNE was documented through patient interviews and review of medical records. Results: Within the analyzed population, 42.4% were in stage G3 (G3a 24.2% and G3b 18.2%), 36.4% were in stage G4, and 21.5% of patients were in stage G5 (according to KDIGO) at the time of evaluation. Regarding treatment before admission, none of the patients had received nsMRA's or GLP1ra. Additionally, only 27-3% were receiving treatment with a RASi, and just 9.1% had previously used iSGLT2. Conclusion: The data analyzed included various clinical variables, CDK stages G3a to G5 (without renal replacement therapy), as well previous use of DNE. Among the clinical variables, advanced age was associated with a higher risk of advanced CKD. The previous use of DNE showed a trend toward a lower risk of advanced CKD, even in elderly patients. These findings reflect a low implementation of pharmacological strategies with proven nephroprotective benefits in patients with advanced Diabetic Kidney Disease. Despite current recommendations from international guidelines, a significant treatment gap persist, possibly due to barriers in medication access, outdated clinical protocols, and limited availability in the public healthcare system. Funding: Government Support – Non-U.S.es_ES
Doihttps://doi.org/10.1681/asn.2025kwhpmakves_ES
URIhttps://riuat.uat.edu.mx/handle/123456789/3349
Idiomaenes_ES
EditorialAmerican Society of Nephrologyes_ES
RelaciónJournal of the American Society of Nephrologyes_ES
URL relacionadohttps://doi.org/10.1681/asn.2025kwhpmakves_ES
DerechosAcceso restringido / Suscripción (Metadatos de producción científica)es_ES
Licenciahttp://purl.org/coar/access_right/c_16eces_ES
FuenteJournal of the American Society of Nephrology
Palabra claveKidney diseasees_ES
Palabra claveDiabetic nephropathyes_ES
Palabra claveDiabetes mellituses_ES
Palabra claveDiseasees_ES
Palabra claveKidneyes_ES
ClasificaciónChronic Kidney Disease and Diabeteses_ES
TítuloTreatment Gap in Nephroprotection: Analysis of Prior Use of Drugs with Nephroprotective Effects in Patients with Incidental Diagnosis of Diabetic Kidney Diseasees_ES
TipoArtículoes_ES
ArbitradoHa sido Arbitradoes_ES
AutorLira, Donna
AutorVelazquez, Jose L.
AutorCastro, Jose Fernando Altamirano
AutorNuñez, Bertha Cadena
AutorGarza, Marcela
AutorLira, Donnaes_ES
AutorVelazquez, Jose L.es_ES
AutorCastro, Jose Fernando Altamiranoes_ES
AutorNuñez, Bertha Cadenaes_ES
AutorGarza, Marcelaes_ES
InstituciónUniversidad Autónoma de Tamaulipas
InstituciónUniversidad Autónoma de Tamaulipases_ES
Número10Ses_ES
URL relacionadahttps://doi.org/10.1681/asn.2025kwhpmakv
Tipo de artículoIndexado
Tipo de artículoIndexadoes_ES
Volumen36es_ES

Files

Collections

Documentación Cientifica